ArticleBiomaterials research2025
(Iso)quinoline-Modified Aza-Boron-Dipyrromethenes Near-Infrared-II Fluorescence/Photoacoustic Nanotheranostics for Cervical Tumor Photothermal Therapy.
Article in Biomaterials research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
NIR-II small-molecule-based bimodal imaging systems accurately unify diagnosis and therapeutics for precision tumor therapy, which is attributed to their easily modifiable structures, high potential biocompatibility. In particular, the highly efficient photodiagnostic agent with high light-to-heat transformation performance and fluorescence/photoacoustic imaging (FLI/PAI) with the range of near-infrared-II (NIR-II; 900 to 1,700 nm) has emerged as a popular research topic. This study reported a series of Aza-boron-dipyrromethenes (Aza-BODIPY) dyes (Aza-A/B/C) with donor-acceptor structure through the introduction of diethylaminobenzene (electron donor) and (iso)quinoline (electron acceptor) into the Aza-BODIPY backbone. Compared to Aza-A/B, the enhanced light trapping ability, the decreased NIR-II fluorescence emission performance, and poor reactive oxygen species generation capacity made Aza-C as an optimal photothermal agent. Through 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-mPEG
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.